Phase 2 RCT in 240 patients with COPD on long-acting bronchodilators: inhaled TQC3721 3 mg and 6 mg improved peak FEV1 at week 4 vs placebo (100 mL and 147 mL); safety was similar to placebo.
RCTn = 240 patients
He et al. Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial